Literature DB >> 12368216

Strain background alters mammary gland lesion phenotype in transforming growth factor-alpha transgenic mice.

Teresa A Rose-Hellekant1, Kennedy Gilchrist, Eric P Sandgren.   

Abstract

Whey acidic protein (WAP)-transforming growth factor (TGF)-alpha transgenic mice acquire both cancerous and noncancerous mammary lesions. For this study, we evaluated the effect of mouse strain background on the incidence, latency, and histotype of two noncancerous lesions, hyperplastic alveolar nodules (analogous to typical hyperplasias in women), and macrocysts. These lesions display characteristics of fibrocystic changes observed in breasts of women, and in both mice and humans are associated with an uncertain risk of progression to neoplasia. Virgin transgenic mice of the (C57BL/6J;SJL)F2 background developed very few hyperplastic alveolar nodules and no macrocysts. In contrast, when the WAP-TGF-alpha transgene was carried on the FVB/N strain, congenic virgin transgenic mice acquired both lesion types with approximately 100% penetrance. In the (FVB;C57BL/6J)F1 background, hyperplastic alveolar nodule incidence was reduced to approximately the nontransgenic mouse level, and macrocyst latency was increased dramatically. Crossing into C57BL/6 resulted in elimination of the macrocyst phenotype. Finally, FVB strain transgenic mammary epithelium transplanted into nontransgenic recipients of the FVB/N or (FVB;C57BL/6J)F1 backgrounds displayed macrocyst latency characteristic of the recipient, and not donor, mouse strain. Quantitative real-time polymerase chain reaction analysis demonstrated that, despite the difference in macrocyst incidence between (FVB;C57BL/6J)F1 and C57BL/6 virgin transgenic mice (81% versus 0%), the level of TGF-alpha expression was not different. FVB strain transgenic mice expressed only twofold more TGF-alpha than the other backgrounds. These findings indicate that C57BL/6J modifier alleles inhibit mammary lesion incidence and macrocyst latency in a semidominant manner, and that suppression of lesion development can involve host factors that are independent of mammary epithelial genotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368216      PMCID: PMC1867309          DOI: 10.1016/s0002-9440(10)64419-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Immunohistochemical study of TGF-alpha, TGF-beta1, EGFR, and IGF-1 expression in human breast carcinoma.

Authors:  M Pilichowska; N Kimura; H Fujiwara; H Nagura
Journal:  Mod Pathol       Date:  1997-10       Impact factor: 7.842

2.  Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops.

Authors:  J S de Jong; P J van Diest; P van der Valk; J P Baak
Journal:  J Pathol       Date:  1998-01       Impact factor: 7.996

3.  Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?

Authors:  R Gerlai
Journal:  Trends Neurosci       Date:  1996-05       Impact factor: 13.837

Review 4.  Cancer resistance genes in mice: models for the study of tumour modifiers.

Authors:  A Balmain; H Nagase
Journal:  Trends Genet       Date:  1998-04       Impact factor: 11.639

5.  Epidermal growth factor and transforming growth factor alpha mRNA expression in human breast cancer biopsies; analysis in relation to estradiol, progesterone and EGF receptor content.

Authors:  N Artagaveytia; S Le Penven; N Falette; R Lucero; E G Garófalo; S Saez
Journal:  J Steroid Biochem Mol Biol       Date:  1997-02       Impact factor: 4.292

6.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

7.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

Review 8.  Etiology of cancer in humans and animals.

Authors:  C P Wild; P Kleihues
Journal:  Exp Toxicol Pathol       Date:  1996-02

Review 9.  Use of transgenic animals in understanding molecular mechanisms of toxicity.

Authors:  C R Wolf; C J Henderson
Journal:  J Pharm Pharmacol       Date:  1998-06       Impact factor: 3.765

10.  Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis.

Authors:  G J Rowse; S R Ritland; S J Gendler
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

View more
  18 in total

1.  Bisphenol A increases mammary cancer risk in two distinct mouse models of breast cancer.

Authors:  Kristen Weber Lozada; Ruth A Keri
Journal:  Biol Reprod       Date:  2011-06-02       Impact factor: 4.285

Review 2.  A visual-quantitative analysis of fibroblastic stromagenesis in breast cancer progression.

Authors:  Edna Cukierman
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-10       Impact factor: 2.673

3.  Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice.

Authors:  Lisa M Arendt; Teresa A Rose-Hellekant; Eric P Sandgren; Linda A Schuler
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex.

Authors:  Michael J Yetman; Sveinung Lillehaug; Jan G Bjaalie; Trygve B Leergaard; Joanna L Jankowsky
Journal:  Brain Struct Funct       Date:  2015-04-14       Impact factor: 3.270

5.  Epidermal growth factor receptor stimulation activates the RNA binding protein CUG-BP1 and increases expression of C/EBPbeta-LIP in mammary epithelial cells.

Authors:  Brenda R Baldwin; Nikolai A Timchenko; Cynthia A Zahnow
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

6.  Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors.

Authors:  Teresa A Rose-Hellekant; Andrew J Skildum; Olga Zhdankin; Amy L Greene; Ronald R Regal; Katherine D Kundel; Donald W Kundel
Journal:  Cancer Prev Res (Phila)       Date:  2009-04-28

7.  Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice.

Authors:  Teresa A Rose-Hellekant; Lisa M Arendt; Matthew D Schroeder; Kennedy Gilchrist; Eric P Sandgren; Linda A Schuler
Journal:  Oncogene       Date:  2003-07-24       Impact factor: 9.867

Review 8.  Transgenic models to study actions of prolactin in mammary neoplasia.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

9.  Extranuclear coactivator signaling confers insensitivity to tamoxifen.

Authors:  Rakesh Kumar; Hao Zhang; Caroline Holm; Ratna K Vadlamudi; Goran Landberg; Suresh K Rayala
Journal:  Clin Cancer Res       Date:  2009-05-26       Impact factor: 12.531

10.  Genetic mapping in mice identifies DMBT1 as a candidate modifier of mammary tumors and breast cancer risk.

Authors:  Anneke C Blackburn; Linda Z Hill; Amy L Roberts; Jun Wang; Dee Aud; Jimmy Jung; Tania Nikolcheva; John Allard; Gary Peltz; Christopher N Otis; Qing J Cao; Reva St J Ricketts; Stephen P Naber; Jan Mollenhauer; Annemarie Poustka; Daniel Malamud; D Joseph Jerry
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.